Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL
2023-505453-40-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 99mTc-EUK-(SO3)CY5-MAS3 in prostate cancer (PCa) (2 arms), sponsored by Netherlands Cancer Institute. Planned start Jul 2025; status: authorised.
02
Drugs
99mTc-EUK-(SO3)CY5-MAS3
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-505453-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505453-40-00.